lazertinib for egfr t790m-mutated nsclc: real-world study | crsf
Published 1 month ago • 12 plays • Length 7:18Download video MP4
Download video MP3
Similar videos
-
57:03
panel discussion | dr krupa shankar | egfr mutant nsclc 1st line long term outcomes
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
35:44
panel discussion | dr ullas batra | hidden egfr threat role of amivantamab
-
18:53
molecular workshop dr anu rasalam iris egfr exon 20 insertions distinct egfr mutations in nsclc with
-
5:45
osimertinib in t790m-mutant lung cancer
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
2:51
early results from a 3rd gen egfr-tki in advanced nsclc
-
2:04
acquired resistance to osimertinib in t790m-positive nsclc
-
15:43
dr. nikhil pandey | elite 24 dec 2021 | how immunotherapy changing the early lung cancer space| csrf
-
1:31
improving radiation for breast cancer
-
9:34
rybrevant/lazertinib for egfrm acquired resistance - asco lung review 2022
-
14:55
advances in diagnosing lung cancer
-
1:11
what is lung cancer?
-
14:23
treatment updates: egfr-mutant lung cancer | 2024 living with egfr-mutant lung cancer patient forum
-
1:19:01
lung cancer what you should know about testing and treatment